Roswell Biotechnologies

The companies will evaluate the usefulness of Roswell's Molecular Electronics platform for drug discovery in neurological, immunological, and rare diseases.

The company's CEO, Paul Mola, said the firm has faced difficulty raising its Series C financing round, which precipitated cuts "across the board" last month.

Researchers said the paper had "impressive" results but that the technology still needs to prove itself with low target concentrations and complex samples.